BEIJING, Feb. 28 -- Chinese scientists have identified a therapeutic target of early-stage hepatocellular carcinoma (HCC), the most common type of primary liver cancer in adults.

HCC is the third leading cause of cancer-related deaths worldwide. Infection with the hepatitis B virus is one of the leading risk factors for developing HCC, particularly in East Asia, according to He Fuchu, chief scientist of the Chinese Human Proteome Project and an academician of the Chinese Academy of Sciences.

Although surgical treatment may be effective in the early stages, the five-year overall rate of survival after developing this cancer is only 50 percent to 70 percent, according to scientists.

Researchers classified the cancer into three sub-types S-I, S-II and S-III. Each of the three sub-types has a different clinical outcome, with S-III associated with the lowest overall rate of survival.

By analyzing the proteomic data of the S-III sub-type, scientists found the therapeutic target called SOAT1. The knockdown of SOAT1 can effectively suppress the proliferation and migration of HCC.

In experiments on mice, they also found that treatment with avasimibe, an inhibitor of SOAT1, markedly reduced the size of tumors that had high levels of SOAT1 expression.

The study provides insight into the tumor biology of this cancer, and suggests opportunities for personalized therapies that target it, He said.

The research was published in the latest issue of the academic journal Nature.

【国内英语资讯:Chinese scientists find therapeutic target of common liver cancer】相关文章：

★ 印度强奸案嫌疑人被起诉

★ 美国商会为中国企业投资美国支招

★ 盘点2011年国内外焦点事件（上）(中英文)

★ 沙特力争提高欧佩克石油产量上限

★ 美国不会跌落财政悬崖

★ 蒙牛纯牛奶强致癌物：黄曲霉素病毒（中英文）

★ 今年过节流行送2012诺亚方舟船票

★ 中海油向美方重新申请收购尼克森

★ 情人节送错礼物 后果很严重

★ 品位名人故居的魅力